Inflammation

CHICAGO — In this video, an expert at NUTRITION discusses ongoing research investigating the role of the gut microbiota in nutrition and inflammation.

CHICAGO — Just 10 minutes of daily moderate exercise may lower inflammation and, subsequently, risk for disease, according to research from the annual NUTRITION meeting.

Topline results from the phase 2b RELIEF trial demonstrate that licaminlimab has the potential to reshape the treatment paradigm of dry eye disease, offering a more precise strategy than current methods.

The European Commission announced approval of dupilumab for treating adults with uncontrolled COPD with type 2 inflammation, according to a press release from Regeneron.

FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.

Matrix metalloproteinase 2 may be associated with the progression of chronic kidney disease, especially in patients with low inflammation or with proteinuria, data show.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Victor Perlroth, MD, CEO of Kodiak Sciences, provides an overview of the company’s ongoing retinal therapy programs.

KIAWAH ISLAND, S.C. — Drug-eluting implants in various stages of study and approval may provide efficient, sustained drug delivery, overcoming barriers to penetration, according to a speaker at Kiawah Eye.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Dilsher S. Dhoot, MD, of California Retina Consultants, discusses positive 40-week data from the phase 1 HELIOS trial.

SAN DIEGO —– New daily persistent headache presents itself relatively early in life, is commonly triggered by stress and leads to stigma and disability, according to a speaker at the American Headache Society Annual Scientific Meeting.